These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28446409)

  • 1. [Evaluation of PFA P2Y assay in monitoring platelet function in elderly patients with cardiovascular disease receiving clopidogrel treatment].
    Tian KP; Guan J; Cai LL; Li YR; Deng XL; Liu QY; Zheng BX; Cong YL
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):533-536. PubMed ID: 28446409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
    Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
    Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
    McGlasson DL; Shah AD; Fritsma GA
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):583-7. PubMed ID: 21799401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
    Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.
    Li S; Choi JL; Guo LZ; Goh RY; Kim BR; Woo KS; Kim MH; Han JY
    Ann Lab Med; 2016 Jan; 36(1):42-8. PubMed ID: 26522758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
    Linnemann B; Schwonberg J; Rechner AR; Mani H; Lindhoff-Last E
    Ann Hematol; 2010 Jun; 89(6):597-605. PubMed ID: 20049442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
    Golański J; Syska K; Chiżynski K; Kassasir H; Watała C; Sakowicz A; Kuliczkowski W
    Pol Arch Med Wewn; 2016 Aug; 126(9):653-661. PubMed ID: 27534914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.
    Jang J; Lim J; Chang K; Kim Y; Kim M; Park HI; Kim J; Shin S
    J Clin Lab Anal; 2012 Jul; 26(4):262-6. PubMed ID: 22811359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy.
    Shao T; Cheng Y; Jin J; Huang L; Yang D; Luo C; Han Z; Wang Z; Ge W; Xu Y
    J Clin Neurosci; 2020 Aug; 78():91-96. PubMed ID: 32624366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
    Lim HH; Li S; An GD; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
    Ann Lab Med; 2018 Sep; 38(5):413-419. PubMed ID: 29797810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.
    Paniccia R; Antonucci E; Gori AM; Marcucci R; Giglioli C; Antoniucci D; Gensini GF; Abbate R; Prisco D
    J Thromb Haemost; 2007 Sep; 5(9):1839-47. PubMed ID: 17723123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures.
    Rolling CC; Tomada J; Frölich AM; Holst B; Holstein K; Voigtländer M; Janjetovic S; Haddad M; Renné T; Fiehler J; Bokemeyer C; Rolling T; Langer F
    Clin Chem Lab Med; 2020 Aug; 59(2):383-392. PubMed ID: 32866112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
    Jover E; Rodríguez JM; Bernal A; Arroyo AB; Iniesta JA; Guiú IS; Martínez C; Vicente V; Lozano ML; Rivera J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):604-11. PubMed ID: 24717421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.
    Slavik L; Ulehlova J; Krcova V; Hlusi A; Indrakova J; Hutyra M; Galuszka J; Indrak K
    Clin Lab; 2014; 60(9):1475-80. PubMed ID: 25291943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention.
    Madsen EH; Saw J; Kristensen SR; Schmidt EB; Pittendreigh C; Maurer-Spurej E
    Clin Chem; 2010 May; 56(5):839-47. PubMed ID: 20224050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.
    Mingant F; Didier R; Gilard M; Martin F; Nicol PP; Ugo V; Lippert E; Galinat H
    Platelets; 2018 May; 29(3):257-264. PubMed ID: 29580115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy.
    Karon BS; Tolan NV; Koch CD; Wockenfus AM; Miller RS; Lingineni RK; Pruthi RK; Chen D; Jaffe AS
    Clin Chem; 2014 Dec; 60(12):1524-31. PubMed ID: 25281703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.